Ganiyu Olatunbosun Arinola
ID
 Email src
Abdulfattah Adekunle Onifade
ID
Kehinde Adigun
ID
Mosunmade Babatunde Oshingbesan
Department of Immunology, University of Ibadan, Nigeria
Department of Immunology, University of Ibadan, Nigeria
Department of Family Planning, University College Hospital, Ibadan, Nigeria
Independent Researcher, Ipswich, United Kingdom
Received: 9 July 2023 / Revised: 18 August 2023 / Accepted: 27 August 2023 / Published: 30 December 2023

Abstract

Introduction and aim. Coronavirus disease 2019 is characterised by cytokine storm and it was managed with repurposed drugs, however the effect of this treatment on cytokine storm is unknown. The aim of the study was to investigate the effect of repurposed management on serum Th1 pro-inflammation cytokine (IFN-γ) and Th2 anti-inflammation cytokine (IL-4) in COVID-19 patients.

Material and methods. The levels of IFN-γ and IL-4 were determined in sera from 45 COVID-19 patients at admission followed-up till discharge after repurposed treatment using ELISA. The mean levels and proportions above normal reference ranges of IFN-γ and IL-4 were compared in COVID-19 at admission and discharge.

Results. The mean values of IFN-γ and IL-4 were significantly higher in COVID-19 patients at admission compared with discharged COVID-19 patients whereas IFN-γ:IL-4 ratio was significantly higher in discharged COVID-19 patients compared with admitted COVID-19 patients. Significantly higher proportion of COVID-19 patients at discharge had IFN-γ within the normal reference ranges compared with COVID-19 patients at admission whereas the proportions of COVID-19 patients at discharge and COVID-19 patients at admission having IL-4 within the normal reference ranges were the same.

Conclusion. Cytokine storm was evidenced in COVID-19 patients at admission and repurposed treatment suppressed pro-inflammation cytokine (IFN-γ) in most discharged COVID-19 patients.

 

Cite

Arinola GO, Onifade AA, Adigun K, Oshingbesan MB. Serum levels of IFN-γ and IL-4 in hospitalised COVID-19 patients – evidence of reduced cytokine storm in discharged patients. Eur J Clin Exp Med. 2023;21(4):750–755. doi: 10.15584/ejcem.2023.4.1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited